ArticleAnnals of surgical oncology2025
Adjuvant Radiation vs Endocrine Therapy After Lumpectomy for Early-Stage Breast Cancer in Older Women: Analysis of Real-World Survival Outcomes.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Radiation De-Escalation in Older Women with Early-Stage ER+/HER2- Invasive Breast Cancer.Annals of surgical oncology · 2026Article
- ASO Author Reflections: Adjuvant Therapy Options for Older Women with Early Stage Breast Cancer.Annals of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundWe examined whether adjuvant radiation therapy (RT) monotherapy offers comparable overall survival (OS) to adjuvant endocrine therapy (ET) monotherapy following lumpectomy in women aged ≥ 65 years with favorable early stage breast cancer. PATIENTS AND
methodsPatients aged ≥ 65 years, diagnosed with ER+/HER2-, cT1-2, N0 breast cancer, who underwent lumpectomy, were selected from the National Cancer Database (2004-2020). Kaplan-Meier estimates and Cox Proportional Hazards models evaluated OS differences across RT-only and ET-only groups.
resultsThe final cohort included 91,505 patients, with 11.8% receiving RT alone and 29.5% receiving ET only. Median follow-up was 67.6 months. ET-only patients were less likely to have a comorbidity score of 0 (ET 75.4% versus RT 80.8%; p < 0.001). Patients in the ET-only group had slightly larger tumors [ET 1.0 cm (0.7-1.5 cm) versus RT 0.9 cm (0.6-1.3 cm); p < 0.001] and were less likely to have grade 3 tumors (ET 7.0% versus RT 8.4%; p < 0.001). Unadjusted Kaplan-Meier analysis showed a higher 5 year OS for RT-only patients compared with ET-only (RT 88.9% versus ET 85.8%; p < 0.001). A similar trend was observed when stratified on the basis of age group (all log rank p < 0.05). In the adjusted multivariable analysis, RT-only remained associated with a slightly better OS than ET-only [ET ref, RT hazards ratio 0.91 (95% CI 0.85-0.97)].
conclusionsFor older patients with early stage, ER+/HER2- breast cancer who undergo lumpectomy, patients receiving RT-only had a small survival advantage over patients receiving ET-only, which may or may not be clinically relevant. Further comparisons of RT-only versus ET-only may be warranted in this unique population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.